BioWorld

Aug. 28, 2007

View Archived Issues

Neurochem Slides 43 Percent On Alzhemed Phase III Failure

After six months of number crunching, Neurochem Inc. confirmed what most analysts already suspected: the North American Phase III trial of Alzhemed (tramiprosate) in Alzheimer's disease did not meet its primary endpoints. (BioWorld Today) Read More

FDA Sends IDM's Junovan Back For More Trial Data

Read More

Stem Cell Transplants Give Hope For Bedside, Lessons For Bench

Read More

BioLineRx Gets BL-4040 Rights; Delves Into Acute Kidney Injury

Read More

Upstream Completes Acquisition Of Firm Focused On Parasites

Read More

Financings Roundup

Read More

Other News To Note

Read More

Clinic Roundup

Read More